Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
163 hedge funds and large institutions have $1.35B invested in Momenta Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 51 reducing their positions, and 27 closing their positions.
361% more call options, than puts
Call options by funds: $2.78M | Put options by funds: $602K
29% more capital invested
Capital invested by funds: $1.05B → $1.35B (+$304M)
27% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 51
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
1.39% less ownership
Funds ownership: 98.36% → 96.97% (-1.4%)
2% less funds holding
Funds holding: 166 → 163 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$31.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.5M |
| 3 |
TA
Teachers Advisors
New York
|
+$9.52M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$8.34M |
| 5 |
VMI
VHCP Management II
New York
|
+$7.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$31.1M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$21.4M |
| 3 |
O
OrbiMed
New York
|
-$15.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.45M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.88M |
MNTA Hedge Fund Activity: Q1 2018 in Review
163 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q1 2018, worth a combined $1.35B — up 29% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MNTA and 26 opened new positions — a net loss of 1 holder — while 51 trimmed existing stakes and 65 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $31.2M. The largest seller was Invesco, cutting an estimated $31.1M.
- 163 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q1 2018, down from 166 in Q4 2017.
- Funds reported $1.35B of Momenta Pharmaceuticals, Inc. stock for Q1 2018, up 29% quarter-over-quarter.
- 26 funds opened new Momenta Pharmaceuticals, Inc. positions in Q1 2018 and 27 closed out, a net change of -1 holder.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q1 2018 was Janus Henderson Group, an estimated $31.2M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q1 2018 was Invesco, an estimated $31.1M sold.
Based on aggregated 13F filings for Q1 2018.